Investors unsure on EyePoint’s Duravyu blockbuster claim

Shares in US retinal diseases specialist EyePoint Pharmaceuticals (Nasdaq: EYPT) recovered from an early nosedive to close trading marginally higher on Wednesday.

Investors were trying to draw conclusions from EyePoint’s presentation of six-month results for the ongoing Phase II VERONA trial of Duravyu (vorolanib intravitreal insert), an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor (TKI) formulated in proprietary bioerodible Durasert E.

EyePoint billed the results as positive, saying the trial met its primary endpoint with extended time to first supplemental injection compared to aflibercept control for both Duravyu doses.